Company News, Regulations

FDA Issues Letter to Soleo of Korea

Agency outlines issues with drug claims and more.

Author Image

By: Christine Esposito

Editor-in-Chief

 The US Food and Drug Administration (FDA) has sent a warning letter to Ji Hyun Min, CEO of Soleo of Korea. FDA conducted an inspection of the company’s drug manufacturing facility from August 6 to 9, 2018. The warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See 21 CFR, parts 210 and 211.   Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CG...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters